poisar

Stocks · News reference

Madrigal Pharmaceuticals Collaborates on Diagnostic Validation of LiquidTransformer

Fiscal.ai

Madrigal Pharmaceuticals collaborated with Hepta on a study validating the LiquidTransformer diagnostic tool using an independent cohort from the company's MASH program.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncKaplan Fox & Kilsheimer Llp

    Kaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations

    Law firm Kaplan Fox is investigating Madrigal Pharmaceuticals for potential securities violations following a whistleblower complaint filed by a former employee alleging retaliation under Sarbanes-Oxley Act provisions. The complaint concerns data and reporting practices. Madrigal's stock declined 8.08% on November 3, 2026, following the disclosure in the company's Form 10-Q filing.

  2. Globenewswire IncKaplan Fox & Kilsheimer Llp

    Kaplan Fox Encourages Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors to Contact the Firm Regarding an Investigation of Possible Securities Law Violations

    Law firm Kaplan Fox is investigating Madrigal Pharmaceuticals following a whistleblower complaint filed by a former employee alleging retaliation under Sarbanes-Oxley Act provisions. The complaint concerns data and reporting practices. Madrigal's stock declined 8.08% on November 3, 2026, following the disclosure in the company's Form 10-Q filing.

  3. Globenewswire IncHagens Berman

    MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns

    Law firm Hagens Berman has launched an investigation into Madrigal Pharmaceuticals following whistleblower allegations of clinical data integrity issues with its drug Rezdiffra. Former SVP Dr. Michael Charlton filed complaints alleging suppression of adverse safety events, discrepancies in efficacy data, and improper board oversight. The disclosure triggered an 8% stock price decline.